Identification of Diagnostic And Prognostic Biomarkers From Amyotrophic Lateral Sclerosis (ALS) Skin and Adipose Samples
| Status: | Completed |
|---|---|
| Conditions: | Neurology, Neurology, Neurology |
| Therapuetic Areas: | Neurology |
| Healthy: | No |
| Age Range: | 19 - Any |
| Updated: | 4/2/2016 |
| Start Date: | July 2008 |
| End Date: | July 2015 |
| Contact: | Cynthia Lary |
| Email: | cynthia.lary@carolinashealthcare.org |
| Phone: | 704-446-6063 |
Identification of Diagnostic and Prognostic Biomarkers From Amyotrophic Lateral Sclerosis (ALS) Skin and Adipose Samples
The purpose of the project is to obtain skin and adipose tissue samples from patients with
ALS to develop new diagnostic and prognostic markers of the disease. These samples will be
obtained when percutaneous endoscopic gastrostomy (PEG) is performed as part of their
standard of care. Skin and adipose tissue samples will also be obtained from disease control
subjects who require a PEG as part of their standard of care.
ALS to develop new diagnostic and prognostic markers of the disease. These samples will be
obtained when percutaneous endoscopic gastrostomy (PEG) is performed as part of their
standard of care. Skin and adipose tissue samples will also be obtained from disease control
subjects who require a PEG as part of their standard of care.
Inclusion Criteria:
- for ALS patients, subjects must be diagnosed with definite ALS according to the El
Escorial Critera (EEC)
- all subjects must be diagnosed with a condition requiring PEG (percutaneous
endoscopic gastrostomy) tube insertion
- subjects must be older than 18 years of age
Exclusion Criteria:
- children 18 years old and younger
We found this trial at
1
site
Click here to add this to my saved trials
